Comparison of nuclear grade and immunohistochemical features in situ and invasive components of ductal carcinoma of breast;Comparação do grau nuclear e perfil imunoistoquímico nos componentes in situ e invasivo de carcinoma mamário

Revista Brasileira de Ginecologia e Obstetricia

Volumn 35, Issue 3, 2013, Pages 97-102

  Aguiar, Fernando Nalesso ^a   Mendes, Henrique Nogueira ^a   Bacchi, Carlos E ^b   Carvalho, Filomena Marino ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b Pathology Consulting Service   (Brazil)

Author keywords

Breast neoplasms chemistry; Carcinoma, ductal, breast chemistry; Immunoenzyme techniques; Keratin 5 analysis; Keratin 6 analysis; Ki 67 antigen analysis; Receptor, erbB 2 analysis; Receptors, estrogen analysis; Tumor makers, biological

Indexed keywords

ADULT; AGED; ARTICLE; BREAST TUMOR; CANCER GRADING; COMPARATIVE STUDY; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; INTRADUCTAL CARCINOMA; MIDDLE AGED; PAGET NIPPLE DISEASE; PATHOLOGY; PREDICTIVE VALUE; PROGNOSIS; TUMOR INVASION; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, INTRADUCTAL, NONINFILTRATING; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM INVASIVENESS; PREDICTIVE VALUE OF TESTS; PROGNOSIS;

EID: 84875722546     PISSN: 01007203     EISSN: None     Source Type: Journal    
DOI: 10.1590/S0100-72032013000300002     Document Type: Article

References (32)

1. Lee S, Stewart S, Nagtegaal I, Luo J, Wu Y, Colditz G, et al. Differentially expressed genes regulating the progression of ductal carcinoma in situ to invasive breast cancer. Cancer Res. 2012;72(17):4574-86.
2. Ernster VL, Ballard-Barbash R, Barlow WE, Zheng Y, Weaver DL, Cutter G, et al. Detection of ductal carcinoma in situ in women undergoing screening mammography. J Natl Cancer Inst. 2002;94(20):1546-54.
3. Buerger H, Otterbach F, Simon R, Schäfer KL, Poremba C, Diallo R, et al. Different genetic pathways in the evolution of invasive breast cancer are associated with distinct morphological subtypes. J Pathol. 1999;189(4):521-6.
4. Hernandez L, Wilkerson PM, Lambros MB, Campion-Flora A, Rodrigues DN, Gauthier A, et al. Genomic and mutational profiling of ductal carcinomas in situ and matched adjacent invasive breast cancers reveals intra-tumour genetic heterogeneity and clonal selection. J Pathol. 2012;227(1):42-52.
5. Johnson CE, Gorringe KL, Thompson ER, Opeskin K, Boyle SE, Wang Y, et al. Identification of copy number alterations associated with the progression of DCIS to invasive ductal carcinoma. Breast Cancer Res Treat. 2012;133(3):889-98.
6. Zikan M, Bohm J, Pavlista D, Cibula D. Comparative analysis of loss of heterozygosity and expression profile in normal tissue, DCIS and invasive breast cancer. Clin Transl Oncol. 2011;13(9):652-5.
7. Lopez-Garcia MA, Geyer FC, Lacroix-Triki M, Marchió C, Reis--Filho JS. Breast cancer precursors revisited: molecular features and progression pathways. Histopathology. 2010;57(2):171-92.
8. Porter D, Lahti-Domenici J, Keshaviah A, Bae YK, Argani P, Marks J, et al. Molecular markers in ductal carcinoma in situ of the breast. Mol Cancer Res. 2003;1(5):362-75.
9. Heaphy CM, Bisoffi M, Joste NE, Baumgartner KB, Baumgartner RN, Griffith JK. Genomic instability demonstrates similarity between DCIS and invasive carcinomas. Breast Cancer Res Treat. 2009;117(1):17-24.
10. Clark SE, Warwick J, Carpenter R, Bowen RL, Duffy SW, Jones JL. Molecular subtyping of DCIS: heterogeneity of breast cancer reflected in pre-invasive disease. Br J Cancer. 2011;104(1):120-7.
11. Steinman S, Wang J, Bourne P, Yang Q, Tang P. Expression of cytokeratin markers, ER-alpha, PR, HER-2/neu, and EGFR in pure ductal carcinoma in situ (DCIS) and DCIS with co-existing invasive ductal carcinoma (IDC) of the breast. Ann Clin Lab Sci. 2007;37(2):127-34.
12. Muggerud AA, Hallett M, Johnsen H, Kleivi K, Zhou W, Tahmasebpoor S, et al. Molecular diversity in ductal carcinoma in situ (DCIS) and early invasive breast cancer. Mol Oncol. 2010;4(4):357-68.
13. Livasy CA, Perou CM, Karaca G, Cowan DW, Maia D, Jackson S, et al. Identification of a basal-like subtype of breast ductal carcinoma in situ. Hum Pathol. 2007;38(2):197-204.
14. Lakhani SR, Ellis IO, Schnitt SJ, Tan PH, van de Vijver MJ. WHO Classification of tumours of the breast. Lyon: IARC; 2012.
15. Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol. 2007;25(1):118-45.
16. Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thürlimann B, Senn HJ, et al. Strategies for subtypes-dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol. 2011;22(8):1736-47.
17. Collins LC, Tamimi RM, Baer HJ, Connolly JL, Colditz GA, Schnitt SJ. Outcome of patients with ductal carcinoma in situ untreated after diagnostic biopsy: results from the Nurses' Health Study. Cancer. 2005;103(9):1778-84.
18. Cuzick J. Treatment of DCIS-results from clinical trials. Surg Oncol. 2003;12(4):213-9.
19. Ottesen GL. Carcinoma in situ of the female breast. A clinicopathological, immunohistological, and DNA ploidy study. APMIS Suppl. 2003;(108):1-67.
20. Park K, Han S, Kim HJ, Kim J, Shin E. HER2 status in pure ductal carcinoma in situ and in the intraductal and invasive components of invasive ductal carcinoma determined by fluorescence in situ hybridization and immunohistochemistry. Histopathology. 2006;48(6):702-7.
21. Steinman S, Wang J, Bourne P, Yang Q, Tang P. Expression of cytokeratin markers, ER-alpha, PR, HER-2/neu, and EGFR in pure ductal carcinoma in situ (DCIS) and DCIS with co-existing invasive ductal carcinoma (IDC) of the breast. Ann Clin Lab Sci. 2007;37(2):127-34.
22. Song WJ, Kim KI, Park SH, Kwon MS, Lee TH, Park HK, et al. The risk factors influencing between the early and late recurrence in systemic recurrent breast cancer. J Breast Cancer. 2012;15(2):218-23.
23. Ishikawa T, Shimizu D, Yamada A, Sasaki T, Morita S, Tanabe M, et al. Impacts and predictors of cytotoxic anticancer agents in different breast cancer subtypes. Oncol Res. 2012;20(2-3):71-9.
24. Sinha S, Singh RK, Bhattacharya N, Mukherjee N, Ghosh S, Alam N, et al. Frequent alterations of LOH11CR2A, PIG8 and CHEK1 genes at chromosomal 11q24.1-24.2 region in breast carcinoma: clinical and prognostic implications. Mol Oncol. 2011;5(5):454-64.
25. Tokunaga E, Okada S, Yamashita N, Akiyoshi S, Kitao H, Morita M, et al. High incidence and frequency of LOH are associated with aggressive features of high-grade HER2 and triple-negative breast cancers. Breast Cancer. 2012;19(2):161-9.
26. Moelans CB, de Wegers RA, Monsuurs HN, Maess AH, van Diest PJ. Molecular differences between ductal carcinoma in situ and adjacent invasive breast carcinoma: a multiplex ligation-dependent probe amplification study. Cell Oncol (Dordr). 2011;34(5):475-82.
27. Moelans CB, Verschuur-Maes AH, van Diest PJ. Frequent promoter hypermethylation of BRCA2, CDH13, MSH6, PAX5, PAX6 and WT1 in ductal carcinoma in situ and invasive breast cancer. J Pathol. 2011;225(2):222-31.
28. Holmes P, Lloyd J, Chervoneva I, Pequinot E, Cornfield DB, Schwartz GF, et al. Prognostic markers and long-term outcomes in ductal carcinoma in situ of the breast treated with excision alone. Cancer. 2011;117(16):3650-7.
29. Lari SA, Kuerer HM. Biological Markers in DCIS and risk of breast recurrence: a systematic review. J Cancer. 2011;2:232-61.
30. Perou CM, Sørlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, et al. Molecular portraits of human breast tumours. Nature. 2000;406(6797):747-52.
31. Nielsen TO, Hsu FD, Jensen K, Cheang M, Karaca G, Hu Z, et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res. 2004;10(16):5367-74.
32. Yu KD, Wu LM, Liu GY, Wu J, Di GH, Shen ZZ, et al. Different distribution of breast cancer subtypes in breast ductal carcinoma in situ (DCIS), DCIS with microinvasion, and DCIS with invasion component. Ann Surg Oncol. 2011;18(5):1342-8.